HOWSON TAMAR D

SEC source: 0001193805-26-000889 · e665609_4-howson.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,370

Underlying: Common Stock · 25,370 shares

Expires 2036-03-27

F1 · shares: Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.

F2 · derivative.exercise_date: The option is fully vested as of March 27, 2026.

SEC source: 0001193805-25-000843 · e664612_4-howson.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2035-06-05

F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date.

SEC source: 0001193805-24-000784 · e663703_4-howson.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-06-11

F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date.

SEC source: 0001193805-24-000325 · e619339_4-howson.xml · derivative · entry 6

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,959

Underlying: Common Stock · 64,959 shares

Expires not disclosed

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.expiration_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-24-000325 · e619339_4-howson.xml · derivative · entry 5

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2032-06-15

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-24-000325 · e619339_4-howson.xml · derivative · entry 4

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2031-06-10

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-24-000325 · e619339_4-howson.xml · derivative · entry 3

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2030-07-02

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-24-000325 · e619339_4-howson.xml · derivative · entry 2

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,986 shares

Expires 2029-10-11

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0001193805-24-000325 · e619339_4-howson.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,973 shares

Expires 2029-10-11

F1 · price: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

F1 · derivative.exercise_date: On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

SEC source: 0000929638-23-002770 · form4.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-09-29

F1 · derivative.exercise_date: Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.

SEC source: 0001193805-23-000923 · e618746_4-howson.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2033-06-28

F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date.

SEC source: 0001209191-23-001785 · doc4.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-01-02

F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

F2 · derivative.exercise_date: This option was granted on January 3, 2023. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date.

SEC source: 0000899243-22-025710 · doc4.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,500

Underlying: Common Stock · 87,500 shares

Expires 2032-07-05

F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months.

SEC source: 0001193805-22-000967 · e621754_4-howson.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-06-15

F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date.

SEC source: 0000899243-22-001050 · doc4.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-01-02

F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

F2 · derivative.exercise_date: This option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date.

SEC source: 0001209191-21-045660 · doc4.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2031-07-01

F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months.

SEC source: 0001193805-21-000867 · e620711_4-howson.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-10

F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date.

SEC source: 0000899243-21-000700 · doc4.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-01-03

F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.

F2 · derivative.exercise_date: This option was granted on January 4, 2021. The shares underlying the option are scheduled to vest in full on the anniversary of the grant date.

SEC source: 0001209191-20-051145 · doc4.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-09-17

F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning March 17, 2021.

SEC source: 0001193805-20-000799 · e619752_4-howson.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-07-01

F1 · derivative.exercise_date: The option vests in monthly increments over a period of one year from the grant date.

SEC source: 0000899243-20-018612 · doc4.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2030-07-02

F1 · derivative.exercise_date: The options will vest in equal monthly installments over twelve months.

SEC source: 0001193805-19-001345 · e619122_4-howson.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,959

Underlying: Common Stock · 29,959 shares

Expires 2029-10-11

F1 · derivative.exercise_date: The option to purchase 9,986 shares vests in monthly increments over a period of one year from the grant date, and the option to purchase 19,973 shares vests in monthly increments over a period of three years from the grant date.

SEC source: 0001209191-19-040974 · doc4.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2029-07-01

F1 · derivative.exercise_date: 20,000 options will vest in equal monthly installments over thirty-six months, and 40,000 of the options will vest in equal monthly installments over twelve months.

SEC source: 0001209191-18-044419 · doc4.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,550

Underlying: Common Stock · 45,550 shares

Expires 2028-07-26

F1 · derivative.exercise_date: The option shares vest and become exercisable in full on the earlier of (i) July 26, 2019 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting.

SEC source: 0001209191-17-050406 · doc4.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,500

Underlying: Common Stock · 42,500 shares

Expires 2027-08-24

F1 · derivative.exercise_date: The option shares vest and become exercisable in full on the earlier of (i) August 24, 2018 or (ii) immediately prior to commencement of the Issuer's next annual stockholder meeting.

SEC source: 0001104659-17-022871 · a4.xml · derivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 35,000 shares

Expires 2027-04-10

F1 · derivative.exercise_date: Options vest in three installments as follows: 11,667 of the options vest on each of April 10, 2018 and 2019 and 11,666 vest on April 10, 2020.

SEC source: 0000014272-06-000229 · how633.xml · derivative · entry 2

HOWSON TAMAR D · CIK 0001202286 · SVP, Corp & Bus Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock, $0.10 par value · 100,000 shares

Expires 2016-11-30

F3 · derivative.exercise_date: Option is not exercisable until the closing share price of common stock achieves a price of at least 15% above the option grant price and remains at that price for seven consecutive trading days. Shares vest one-third per year, on a cumulative basis, on the third, fourth, and fifth anniversaries of the grant date.

SEC source: 0000014272-06-000229 · how633.xml · nonDerivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · SVP, Corp & Bus Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,465

F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock.

F2 · balance_after: Includes shares of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.

SEC source: 0000014272-06-000185 · how596.xml · nonDerivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · SVP, Corp & Bus Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,503

F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock.

SEC source: 0000014272-06-000147 · how566.xml · nonDerivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · SVP, Corp & Bus Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,718

F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock.

SEC source: 0000014272-06-000100 · how530.xml · derivative · entry 4

HOWSON TAMAR D · CIK 0001202286 · SVP, Corp & Bus Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,915

Underlying: Common Stock, $0.10 par value · 33,915 shares

Expires 2016-03-06

F4 · derivative.exercise_date: Option is not exercisable until the closing share price of common stock achieves a price of at least 15% above the option grant price and remains at that price for seven consecutive trading days. Option vests 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant, but may not be exercised until the threshold is satisfied.

SEC source: 0000014272-06-000100 · how530.xml · nonDerivative · entry 3

HOWSON TAMAR D · CIK 0001202286 · SVP, Corp & Bus Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,756

F3 · shares: Shares withheld for payment of taxes.

SEC source: 0000014272-06-000100 · how530.xml · nonDerivative · entry 2

HOWSON TAMAR D · CIK 0001202286 · SVP, Corp & Bus Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,618

F2 · shares: Consists of shares earned as long-term performance awards under the 2002 Stock Incentive Plan.

SEC source: 0000014272-06-000100 · how530.xml · nonDerivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · SVP, Corp & Bus Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,511

F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.

SEC source: 0000014272-05-000199 · how467.xml · nonDerivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · SVP, Corp & Bus Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,426

F1 · kind: Shares withheld for payment of taxes upon vesting of restricted stock.

F2 · balance_after: Includes shares of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.

SEC source: 0000014272-05-000123 · how399.xml · nonDerivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · SVP, Corp & Bus Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,720

F1 · kind: Shares withheld for payment of taxes upon vesting of restricted stock.

SEC source: 0000014272-05-000072 · how365.xml · derivative · entry 2

HOWSON TAMAR D · CIK 0001202286 · SVP, Corp & Bus Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,667

Underlying: Common Stock, $0.10 par value · 46,667 shares

Expires 2015-02-28

F2 · derivative.exercise_date: Option is not exercisable until the earlier of (i) the closing share price of common stock achieving a price of at least 15% above the option grant price and remaining at that price for seven consecutive trading days or (ii) the ninth anniversary of the grant date. Shares underlying option vest 25% a year, on a cumulative basis, commencing one year after the date of grant.

SEC source: 0000014272-05-000072 · how365.xml · nonDerivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · SVP, Corp & Bus Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,180

F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.

SEC source: 0000014272-04-000196 · how322.xml · nonDerivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · SVP, Corp & Bus Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,402

F1 · kind: Shares withheld for payment of taxes upon vesting of restricted stock.

F2 · balance_after: Includes shares of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.

SEC source: 0000014272-04-000073 · how231.xml · derivative · entry 2

HOWSON TAMAR D · CIK 0001202286 · SVP, Corp & Bus Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,667

Underlying: Common Stock, $0.10 par value · 46,667 shares

Expires 2014-03-01

F2 · derivative.exercise_date: Exercisable as to 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant.

SEC source: 0000014272-04-000073 · how231.xml · nonDerivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · SVP, Corp & Bus Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,862

F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.

SEC source: 0000014272-03-000030 · how159.xml · nonDerivative · entry 1

HOWSON TAMAR D · CIK 0001202286 · SVP, Corp & Bus Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,084

F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.